QUALITATIVE AND QUANTITATIVE ANALYTICAL METHOD FOR ANALYZING THE ACTIVITY TYPE OF AN ENZYME THAT IS ACTIVATED BY PROTEOLYSIS
    91.
    发明申请
    QUALITATIVE AND QUANTITATIVE ANALYTICAL METHOD FOR ANALYZING THE ACTIVITY TYPE OF AN ENZYME THAT IS ACTIVATED BY PROTEOLYSIS 审中-公开
    用于分析通过蛋白激活的酶活性类型的定性和定量分析方法

    公开(公告)号:WO2011149272A2

    公开(公告)日:2011-12-01

    申请号:PCT/KR2011003843

    申请日:2011-05-25

    CPC classification number: G01N33/573 C12Q1/25 C12Q1/37 G01N2500/00 G01N2800/52

    Abstract: The present invention relates to a qualitative and quantitative analytical method for analyzing the activity type of an enzyme that is activated by proteolysis. The method of the present invention is advantageous in that the activity type of an enzyme present in a specimen is analyzed using an enzyme activity inhibitor and a binder to enable the analysis to be performed in a quicker and more accurate manner as compared to enzyme-activity analysis methods using a simple binder (for example, an antibody). The method of the present invention can enable the analysis of the activity type of an enzyme present in a specimen in a simple manner using less equipment than enzyme-activity analysis methods using a simple binder. The method of the present invention involves simultaneously using the inhibitor and the binder in analyzing the activity type of a target enzyme or an enzyme to enable quick and specific analysis, and high-throughput drug screening can be performed at a high speed due to the above-described characteristics of the method of the present invention. In addition, the method of the present invention can be applied to point-of-care testing (POCT) for the clinical monitoring of the effects and dosage of a drug in a drug administration target (for example, an animal or human).

    Abstract translation: 本发明涉及用于分析通过蛋白水解活化的酶的活性类型的定性和定量分析方法。 本发明的方法的优点在于,使用酶活性抑制剂和粘合剂分析存在于样品中的酶的活性类型,以便能够以比酶活性更快和更准确的方式进行分析 使用简单粘合剂(例如抗体)的分析方法。 本发明的方法可以使用简单的粘合剂使用比酶活性分析方法更少的设备,以简单的方式分析存在于样品中的酶的活性类型。 本发明的方法包括同时使用抑制剂和粘合剂分析目标酶或酶的活性类型以进行快速和特异性分析,并且由于上述可以高速进行高通量药物筛选 描述了本发明方法的特征。 此外,本发明的方法可以应用于临床监测药物给药靶标(例如动物或人)中药物的作用和剂量的护理点测试(POCT)。

    METHOD FOR SCREENING FOR AGENTS THAT MODULATE THE ACTIVITY OF THE MDM2 UBIQUITIN LIGASE AND MEANS FOR IMPLEMENTING SAID METHOD
    93.
    发明申请
    METHOD FOR SCREENING FOR AGENTS THAT MODULATE THE ACTIVITY OF THE MDM2 UBIQUITIN LIGASE AND MEANS FOR IMPLEMENTING SAID METHOD 审中-公开
    用于筛选用于调节MDM2 UBIQUITIN LIGASE的活性的试剂的方法和用于实施所述方法的方法

    公开(公告)号:WO2009080981A3

    公开(公告)日:2009-08-27

    申请号:PCT/FR2008052258

    申请日:2008-12-09

    CPC classification number: C12Q1/025 C12Q1/25 G01N2333/9015

    Abstract: The subject of the invention is an in cellulo method for screening for agents that modulate the activity of the Mdm2 ubiquitin ligase, said method comprising the following steps: a) bringing a candidate test agent into contact with recombinant yeast cells which express, in the nucleus thereof, a fusion protein comprising: (i) a polypeptide MDM2 and (ii) at least one detectable protein; b) quantifying said first detectable protein in the yeast cells, at the end of at least one predetermined period of time after the candidate agent has been brought into contact with said cells; c) comparing the value obtained in step (b) with a control value obtained when step (a) is carried out in the absence of the candidate agent.

    Abstract translation: 本发明的主题是用于筛选调节Mdm2泛素连接酶活性的试剂的cellulo方法,所述方法包括以下步骤:a)使候选试剂与在细胞核中表达的重组酵母细胞接触 其包含:(i)多肽MDM2和(ii)至少一种可检测蛋白质; b)在候选药剂与所述细胞接触后至少一个预定时间段结束时,定量酵母细胞中的所述第一可检测蛋白质; c)将步骤(b)中获得的值与在没有候选代理的情况下执行步骤(a)时获得的控制值进行比较。

    TRIM24 (TIFLA) AS P53 MODULATOR AND CANCER TARGET
    94.
    发明申请
    TRIM24 (TIFLA) AS P53 MODULATOR AND CANCER TARGET 审中-公开
    TRIM24(TIFLA)AS P53调节器和癌症目标

    公开(公告)号:WO2009004484A3

    公开(公告)日:2009-08-20

    申请号:PCT/IB2008002504

    申请日:2008-07-03

    Inventor: BARTON MICHELLE

    Abstract: Methods of screening for modulators of TRIM24 (also known as TIF1 -ALPHA) expression and/or biological activity are described. In particular, methods of screening of screening for modulators of TRIM24 E3 ligase activity, and specifically an E3 ligase activity directed at p53 as the target polypeptide are also described. Modulators of TRIM24 expression and activity are provided and their use in treatment of cancer, particularly in breast, colon, prostate, renal cancers and in acute lymphoblastic leukaemia. Suitable modulators of TRIM24 expression include siRNA and shRNA and can be used in the treatment of cancer and for targeting cancer stem cells.

    Abstract translation: 描述了对TRIM24(也称为TIF1-ALPHA)表达和/或生物活性的调节剂的筛选方法。 特别地,还描述了筛选TRIM24 E3连接酶活性的调节剂的筛选方法,特别是针对p53作为靶多肽的E3连接酶活性的方法。 提供TRIM24表达和活性的调节剂及其在治疗癌症中的用途,特别是在乳腺癌,结肠癌,前列腺癌,肾癌和急性淋巴细胞性白血病中的应用。 TRIM24表达的合适调节剂包括siRNA和shRNA,可用于治疗癌症和靶向癌症干细胞。

    IMPROVED DETECTION OF MI CRO-ORGT-NI SMS
    97.
    发明申请
    IMPROVED DETECTION OF MI CRO-ORGT-NI SMS 审中-公开
    改进MI CRO-ORGT-NI SMS的检测

    公开(公告)号:WO2009007719A2

    公开(公告)日:2009-01-15

    申请号:PCT/GB2008002354

    申请日:2008-07-09

    Abstract: NAD-dependent ligase is identified as an indicator of micro¬ organisms in a sample. A method of detecting the presence of an NAD-dependent ligase expressing micro-organism in a sample comprises the steps of: (a) contacting the sample with a nucleic acid molecule which acts as a substrate for NAD-dependent ligase activity in the sample, (b) incubating the thus contacted sample under conditions suitable for NAD-dependent ligase activity; and (c) specifically determining the presence of a ligated nucleic acid molecule resulting from the action of the NAD- dependent ligase on the substrate nucleic acid molecule to indicate the presence of the NAD-dependent ligase expressing micro-organism. The method has a number of applications and kits for carrying out the methods are also provided. Lysostaphin preparations substantially free from nuclease and/or ligase contaminants are produced by heating a lysostaphin preparation which contains nuclease and/or ligase contaminants under conditions whereby nuclease and/or ligase activity is reduced whereas endopeptidase activity of the lysostaphin is substantially unaffected.

    Abstract translation: NAD依赖性连接酶被鉴定为样品中微生物的指标。 检测样品中NAD依赖性连接酶表达微生物的存在的方法包括以下步骤:(a)使样品与作为样品中NAD依赖性连接酶活性的底物的核酸分子接触, (b)在适合于NAD依赖性连接酶活性的条件下孵育由此接触的样品; 和(c)具体确定由NAD依赖性连接酶在底物核酸分子上的作用产生的连接的核酸分子的存在,以指示表达微生物的NAD依赖性连接酶的存在。 该方法还提供了许多用于执行方法的应用和套件。 通过在其中核酸酶和/或连接酶活性降低的条件下加热含有核酸酶和/或连接酶污染物的溶葡萄球菌素制剂而产生基本上不含核酸酶和/或连接酶污染物的溶葡萄球菌素制剂,而溶葡萄球菌素的内肽酶活性基本上不受影响。

    PADLOCK PROBE AMPLIFICATION METHODS
    98.
    发明申请
    PADLOCK PROBE AMPLIFICATION METHODS 审中-公开
    PADLOCK探针放大方法

    公开(公告)号:WO2009006907A1

    公开(公告)日:2009-01-15

    申请号:PCT/DK2008/050174

    申请日:2008-07-09

    Abstract: The present invention relates to an enzyme activity assay using rolling circle 5 amplification for verifying that a sample contains enzyme activity. The enzyme activity assayed is typically involved in processing of mismatched nucleotides and/or damaged nucleotides in a double stranded nucleic acid. The present invention relates to methods for determining the presence of enzyme activities involved in processing double stranded oligonucleotide. Methods are also directed against determining the presence 10 of nucleotide repair enzyme activities involved in the repair of a circular oligonucleotide. The present invention also relates to liquid compositions and solid support both comprising an oligonucleotide probe. Furthermore, the present invention relates to methods for testing the efficacy of a drug, for diagnosing, prognosing, treating a disease by determining the enzyme activity.

    Abstract translation: 本发明涉及使用滚圈5扩增用于验证样品含有酶活性的酶活性测定法。 测定的酶活性通常参与双链核酸中错配核苷酸和/或受损核苷酸的加工。 本发明涉及用于测定涉及加工双链寡核苷酸的酶活性的存在的方法。 方法还针对确定涉及修饰圆形寡核苷酸的核苷酸修复酶活性的存在10。 本发明还涉及包含寡核苷酸探针的液体组合物和固体支持物。 此外,本发明涉及通过测定酶活性来测定药物的功效,用于诊断,预测,治疗疾病的方法。

    タンパク質および核酸の超高感度測定法
    99.
    发明申请
    タンパク質および核酸の超高感度測定法 审中-公开
    蛋白质或核酸的超敏感测量方法

    公开(公告)号:WO2008117816A1

    公开(公告)日:2008-10-02

    申请号:PCT/JP2008/055664

    申请日:2008-03-26

    Applicant: 伊藤 悦朗

    Inventor: 伊藤 悦朗

    CPC classification number: C12Q1/32 C12Q1/25 G01N33/5735 G01N33/6803

    Abstract: 吸光光度計やプレートリーダー等の汎用測定機器や目視で測定可能な超高感度測定法を提供する。チオNAD(P)を補酵素とする酵素サイクリング法と標識酵素およびその基質の最適な組合わせにより、シグナル物質であるチオNAD(P)Hを幾何級数的に増幅し、そのチオNAD(P)Hを比色定量することにより、汎用測定機器や目視で測定可能な高感度測定法を提供することができる。

    Abstract translation: 公开了一种超灵敏的测量方法,其可以在目视上或在诸如吸收分光光度计或读板器读板器的通用测量装置上实现测量。 具体公开了一种高灵敏度的测量方法,其可以在目视或通用测量装置上实现测量,其特征在于以指数方式放大硫代NAD(P)H(其为信号物质),并且通过比色测量 通过采用使用硫代NAD(P)作为辅酶与标记酶的酶循环方法和用于标记酶的底物的最佳组合的硫代NAD(P)H。

    AGENTS AND METHODS TO ELICIT ANTI-TUMOR IMMUNE RESPONSE
    100.
    发明申请
    AGENTS AND METHODS TO ELICIT ANTI-TUMOR IMMUNE RESPONSE 审中-公开
    诱导抗肿瘤免疫应答的试剂和方法

    公开(公告)号:WO2008033403A3

    公开(公告)日:2008-07-24

    申请号:PCT/US2007019824

    申请日:2007-09-13

    Abstract: The invention provides an isolated, purified population of human cells comprising CD8+ T cells with reduced Cbl-b activity. The invention provides uses of such cells in methods for inducing or enhancing an anti-tumor immune response in a subject. These methods comprise: (a) providing a cell population, from a subject or from another source, which comprises CD8+ T cells, (b) reducing Cbl-b activity in the CD8+ T-cells, (c) administering the cells of step (b) to the subject. The invention provides methods for making CD8+ T cells that do not require stimulation through a co-receptor in order for the cell to become activated or proliferated in response to contact via its T cell receptor. Such methods are based upon reducing function of Cbl-b. The invention also provides methods for identifying agents which affect Cbl-b expression or activity.

    Abstract translation: 本发明提供了分离的纯化的人细胞群,其包含具有降低的Cbl-b活性的CD8 + T细胞。 本发明提供了这些细胞在诱导或增强受试者中的抗肿瘤免疫应答的方法中的用途。 这些方法包括:(a)提供来自受试者或来自另一来源的包含CD8 + T细胞的细胞群,(b)降低CD8 + T细胞中的Cbl-b活性,(c)将步骤 b)主题。 本发明提供了制备不需要通过共受体刺激的CD8 + T细胞的方法,以便细胞响应经由其T细胞受体的接触而被激活或增殖。 这些方法基于减少Cbl-b的功能。 本发明还提供了鉴定影响Cbl-b表达或活性的试剂的方法。

Patent Agency Ranking